ProPhase Labs Profit Margin

The latest profit margin for PRPH is -7.09% as of March 2026. That compares with -9.44% in the prior-year period — up 24.9% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside ProPhase Labs's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRPH's profit margin moved from -9.44% to -7.09% — a 24.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ProPhase Labs's valuation or profitability profile.

Against Healthcare companies, PRPH currently prints -7.09% for profit margin, while the sector average sits near 15.52%. That is roughly 4670.8% below the sector mean. Large gaps often invite a closer look at ProPhase Labs's growth, margins, and balance sheet.

Profit Margin shows how effectively ProPhase Labs converts resources into returns. At -7.09%, PRPH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -9.44% in the prior-year period — up 24.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PRPH's profit margin (-7.09%), review year-over-year change from -9.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.